No peer-reviewed human studies specifically measuring CJC-1295 administered as a nasal spray were identified in the scientific literature reviewed for this article. This means that, although CJC-1295 nasal sprays are sold commercially, their effectiveness compared to injection has not been established through independent, published research. This is a distinction worth understanding clearly before we look at what is known and what is not.
What is CJC-1295 nasal spray?
CJ C-1295 nasal spray is a liquid peptide formulation designed for absorption through the nasal mucosa—the moist tissue lining the inside of the nose—rather than subcutaneous injection. Products of this type are currently sold by various commercial sources as an alternative to subcutaneous injections. The underlying concept is not fundamentally implausible. The idea is that the peptide could be absorbed by the nasal lining and thereby enter the bloodstream. The nasal mucosa is indeed richly vascularized and is a recognized route of administration for many other peptide-based drugs in general medicine.
However, it is important to make a clear distinction here. „The concept is plausible” and „this specific product has been proven to work” are two very different claims. The peer-reviewed literature reviewed for this article does not contain a dedicated pharmacokinetic study measuring how much CJC-1295 specifically is actually absorbed into the bloodstream when administered as a nasal spray. Nor does it measure what hormonal effect, if any, results from this route of administration.
How effective is CJC-1295 nasal spray?
Without a dedicated study on the intranasal bioavailability of CJC-1295, this question cannot be answered directly based on the available evidence. However, there are relevant comparative data from a closely related compound that provide useful context. A controlled pharmacokinetic study of ipamorelin—a ghrelin receptor peptide often combined with CJC-1295—directly tested intranasal administration in animal studies. It showed that bioavailability via this route is approximately 20%. This means that roughly one-fifth of the dose reached the systemic circulation compared to injection. This was significantly lower than that of some structurally related peptides tested in the same study, several of which exhibited bioavailability closer to 50% [1].
This tells us two useful things. First, these related growth hormone-releasing peptides, as a chemical family, are capable of at least some nasal absorption. So the underlying biology is not implausible. Second, the effectiveness of nasal absorption varies significantly between individual peptides, even within the same structural family. This means the nasal bioavailability numbers for ipamorelin cannot simply be assumed to be equally applicable to CJC-1295 - a chemically distinct and significantly larger molecule, especially in its DAC-conjugated form.
Without dedicated research, no evidence-based bioavailability percentage or efficacy comparison with injection can be provided specifically for CJC-1295 nasal spray. Any such numbers appearing in the commercial marketing of these products should be understood as a manufacturer's claim, not independently verified research.
Dosage and usage of CJC-1295 nasal spray
No published pharmacokinetic or clinical studies have established that CJC-1295 nasal spray reliably delivers an effective dose of the peptide into the bloodstream. For this reason, this article does not provide dosing, usage instructions, or frequency recommendations for this product. To do so would require making up numbers that do not exist within the evidence base of peer-reviewed literature. This gap is more significant than it might initially seem. Even if the nasal spray contains the precisely labeled amount of CJC-1295 in the bottle, the actual amount absorbed into the bloodstream after nasal spray administration depends on numerous physiological factors. These include the condition of the nasal mucosa, the technique used, and individual variability between people—none of which have been studied for this particular compound. This means the labeled dose and the effective dose could differ significantly in ways that are simply not known.
This article also does not recommend or point to any specific provider or retail source for these products. This aligns with a broader, memorable principle: unregulated peptide products, including specialized delivery formats like nasal sprays, carry documented concerns regarding product quality, purity, and accurate labeling. These concerns have been raised in reviews of this class of compounds more broadly [2].
Limitations of current evidence
The central limitation running through this entire topic is simple. CJC-1295 nasal spray is a commercially available product, but it is not scientifically studied—at least, based on the peer-reviewed literature reviewed for this article.
The data that actually exists regarding the nasal bioavailability of ipamorelin provides informative background to the general concept of intranasal peptide delivery. However, it cannot be used to draw definitive conclusions specifically about CJC-1295, as that is a different, structurally distinct molecule that was not tested via this route in any study identified herein.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as medical advice, dosing guidance, or product endorsement. CJC-1295, in any form of administration, is a research compound and is not approved by the FDA or the European Medicines Agency for any medical use. No published pharmacokinetic or clinical studies have measured the absorption, efficacy, or safety of CJC-1295 administered specifically as a nasal spray. Commercial claims concerning the bioavailability or effectiveness of nasal spray administration have not been independently verified through peer-reviewed studies.
References
[1] Johansen, P. B., Hansen, K. T., Andersen, J. V., & Johansen, N. L. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica, 28(11), 1083–1092. https://doi.org/10.1080/004982598238976
[2] Coutinho, L. F. D., De Oliveira Neves, L. F., & Camilo, R. P. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: A critical review. Journal of Sports Medicine and Physical Fitness, 66(7), 880–885. https://doi.org/10.23736/S0022-4707.26.17773-1